Cell Painting – Molecular Imaging in Drug Discovery
Drug discovery is the process by which potential new medicines are identified, repurposed and/or designed. This involves a wide [...]
Cell-Subtype Selection in the Creation of a 3D Liver Fibrosis Model
Griffin Ferrara2021-03-19T14:18:00-05:00Highlights 3D liver fibrosis models typically incorporate both hepatocytes and various non-parenchymal (NPC) populations. Stimulation of these models [...]
Bruker and Visikol Partner to Launch Light-Sheet Imaging Services
Hampton, NJ – March 9th, 2021 – Visikol today announced its partnership with Bruker to use Bruker’s flagship MuVi [...]
Visikol Expands Product Portfolio with New Tissue Slicers
Visikol was originally founded as a products oriented company when it launched its Visikol® HISTO™ portfolio of reagents and [...]
Visikol named to Pharma Tech Outlook’s Top Emerging Pharma Outsourcing Companies of 2021
Pharma Tech Outlook acknowledges Visikol and how the company is leveraging its advanced imaging and 3D cell culture solutions [...]
Using Noise Reduction Methods in ImageJ to Produce High Quality Data
work with us After completing the imaging process for your desired biological model, you may find [...]
Leica Biosystems and Visikol to Host Multiplex Webinar
Visikol CEO Dr. Michael Johnson will be hosting a webinar with Leica Biosystems discussing multiplex imaging and the Leica [...]
Our Multiplex Immunolabeling Approach
Griffin Ferrara2021-02-03T15:56:14-05:00Immunohistochemistry is routinely used to localize and study the distribution of proteins in tissues. Most staining methods are limited [...]
Visikol Launches BitSlide, Cloud-Based Digital Pathology Slide Visualization Platform
Visikol has been a leader in advanced bioimaging through its portfolio of cutting-edge technologies and innovative drug discovery, bioimaging, [...]
Using Immunohistochemistry and Multiplex Slide Labeling for Tumor Research
Accurate prediction and prognosis as well as patient stratification for precision therapy are the most important and difficult issues [...]